1. Home
  2. MERC vs LUNG Comparison

MERC vs LUNG Comparison

Compare MERC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercer International Inc.

MERC

Mercer International Inc.

HOLD

Current Price

$0.90

Market Cap

56.9M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.37

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MERC
LUNG
Founded
1968
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Paper
Industrial Specialties
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.9M
57.9M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
MERC
LUNG
Price
$0.90
$1.37
Analyst Decision
Hold
Buy
Analyst Count
3
7
Target Price
$2.25
$5.38
AVG Volume (30 Days)
489.8K
330.3K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
7.01%
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$1,169,145,000.00
$90,497,000.00
Revenue This Year
$13.75
$2.48
Revenue Next Year
$10.12
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
25.50
8.01
52 Week Low
$0.75
$1.13
52 Week High
$4.47
$3.88

Technical Indicators

Market Signals
Indicator
MERC
LUNG
Relative Strength Index (RSI) 44.93 47.35
Support Level $0.75 $1.36
Resistance Level $1.20 $1.45
Average True Range (ATR) 0.08 0.11
MACD 0.01 -0.02
Stochastic Oscillator 41.49 23.29

Price Performance

Historical Comparison
MERC
LUNG

About MERC Mercer International Inc.

Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: